Join our daily newsletter At The Bell to receive exclusive market insights
- Chimeric Therapeutics (CHM) will progress to the second dose level of its clinical trial after confirming no dose-limiting toxicities in the first patient cohort
- The phase one dose escalation study is assessing the safety and maximum tolerated dose of Chimeric’s cell therapy, Chlorotoxin CAR T (CLTX CAR T)
- CLTX CAR T is unique in using chlorotoxin, a peptide derived from scorpion toxin, as the tumour-targeting component of the chimeric antigen receptor
- The initial patient dosing concluded in March and after completing a 28-day follow-up period, no patient has reported dose limiting toxicities.
- The second dose level will administer the CAR T cells by two routes, intratumoral and intracranial intraventricular
- Shares are 1.7 per cent higher trading at 30 cents each
Chimeric Therapeutics (CHM) will progress to the second dose level of its clinical trial after confirming no dose-limiting toxicities in the first patient cohort.
The phase one dose escalation study is assessing the safety and maximum tolerated dose of Chimeric’s cell therapy, Chlorotoxin CAR T (CLTX CAR T), which is the first of its kind and has the potential to address unmet medical needs of patients with recurrent or progressive glioblastoma.
CLTX CAR T is unique in using chlorotoxin (CLTX), a peptide derived from scorpion toxin, as the tumour-targeting component of the chimeric antigen receptor (CAR).
The phase one study aims to enrol between 18 and 36 patients with MMP2+ recurrent or progressive glioblastoma across four dose levels.
The initial patient dosing concluded in March and after completing a 28-day follow-up period, no patient has reported experiencing dose limiting toxicities.
Consequently, the company can advance to the second dose level, which will administer the CAR T cells by two routes, intratumoral and intracranial intraventricular.
Chimeric’s CEO, Jennifer Chow said the announcement is a significant milestone for the company, enabling the advancement of an important therapy for patients with progressive or recurrent glioblastoma.
The initial dosing was staggered to monitor any adverse events between dosings, however, the next stage will enable patient dosing without a mandated stagger.
The clinical trial is taking place at City of Hope, a world-renowned cancer research and treatment centre near Los Angeles.
Shares are 1.7 per cent higher trading at 30 cents each at 10:38 am AEST.
